semaglutide diabetes trial Cardiovascular Outcomes (CVOT) Oral Semaglutide Lowers HbA1c in

Reduced appetite makes it harder to meet nutritional targets through traditional eating patterns

Whats next for this research

Moving Forward Rheumatologists and healthcare providers need to explore innovative strategies for addressing the long-term cardiovascular risks in their autoimmune patients

During your consultation, Ellie Adams, FNP-BC, will determine whether tirzepatide (the active ingredient in Zepbound and Mounjaro) or semaglutide (the active ingredient in Wegovy and Ozempic) is appropriate for your individualized treatment plan

Wegovy reduces appetite and food intake, which may inadvertently lead to inadequate protein consumption